More Videos
SPECIAL REPORT
MOST SHARED
- Dubai Fallout Is a Correction, Not Another Crisis: El-Erian
- Finding the Holiday's Best Buys
- 8 Retailers that Gain During the Holidays
- Banks Play Down Dubai Exposure, Investors Still Wary
- More Asia Executives Resigned to Economy Flights: Survey
- Shoppers Hit Black Friday Sales, Budgets Pared
- US Markets Bracing for Selloff On Worries About Dubai's Debt
- Attraction of Switzerland to Businesses
- San Miguel Sells $1.36 Billion Stake to Ally
- Is Super Bowl Halftime Act Too Old?
- Surprising Options Trades in TiVo Shares
- EA Sports Hopes to Pump Up Sales Through Pop-Up Locations
- 8 Retailers that Gain During the Holidays
- Farrell: What's Different On This Black Friday
- 10 Dividend Picks For Your Portfolio: Chief Investors
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Dubai Fallout Is a Correction, Not Another Crisis: El-Erian
- Dubai's Debt Woes Signal New Era for Creditors
- Banks With The Biggest Exposure to The UAE
- Slideshow: The World's Biggest Debtor Nations
- US Dollar Rises Against Most Currencies—Except Yen
- Shoppers Hit Black Friday Sales, Budgets Pared
- Slideshow: Fantasy Christmas Gifts 2009
- EA Sports Hopes to Pump Up Sales With Pop-Ups
- Cheap Robotic Hamsters Are Holiday's Unlikely Craze
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
Given investor reaction to the Vytorin/Zetia news yesterday, you might draw the conclusion the huge cholesterol drug franchise might be doomed.
Sure, analysts say, prescriptions and sales are gonna go down some more, but they're not going to zero. The drug may not have been effective as had been hoped against a key heart disease measure, but it did lower bad cholesterol, triglycerides and a marker for heart attack risk more than Zocor alone.
And MRK [MRK
Loading...
()
] and SGP [SGP
Loading...
()
] are already trying to promote that fact. Check out the two-page ad the companies took out in today's USA Today sports section. (The first page is the true ad, the second page is all the fine print on the label about side effects and stuff.)
What I think is most notable about the message is that they come right out with it--and in boldface type, no less: "VYTORIN has not been shown to reduce heart attacks or strokes more than Zocor alone." 
On the flip side Pfizer [PFE
Loading...
()
] has taken out a big ad in the Newark Star-Ledger (most of the large drug companies have major operations or their HQ in Jersey and tens of thousands of employees live there) for the past couple days. The copy says: "Now you know. There's an important difference between Vytorin, Zetia, and Lipitor. Unlike Vytorin and Zetia, Lipitor is FDA-approved to reduce the risk of heart attacks, strokes...."
And now even the editorial cartoonists are jumping into the fray. Today's Star-Ledger opinion page features this little gem on Vytorin: "Take twice a day for no good reason. Side effects: falling stock prices, reduced executive bonuses, uncontrollable CEO weeping, job loss." 
But in all seriousness, the Vytorin/Zetia aftermath may not be Schering's only challenge. There's a slew of analyst commentary and at least a couple of upgrades on Vertex Pharmaceuticals [VRTX
Loading...
()
] this morning.
What does that have to do with SGP? Well, the companies are racing to get new drugs approved for hepatitis c and based on new data many analysts are saying it looks like VRTX's drug might be better than they thought it was and possibly better than Schering's.
In an exclusive interview with Jim Cramer on "Mad Money" last night SGP CEO Fred Hassan said, "This is a broad, strong company."
Its strength is certainly being put to the test.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes